, Responder rate (%) N/A +22.9 (P = 0.027) +26.5 (P = 0.029) PDA treatment period (%), CfB in TAC (g/day)
, CfB in HDD (HDD/month)
GABA (A) receptors are high-affinity targets for ?-hydroxybutyric acid (GHB), Three patients had unknown DRL at baseline and were not included in this table. References Absalom N, vol.109, pp.13404-13409, 2012. ,
4-Hydroxybutyrate anaesthesia for cardiovascular surgery. A comparison with halothane, Anaesthesia, vol.23, pp.558-565, 1968. ,
Dynorphin and ?-opioid receptor dysregulation in the dopaminergic reward system of human alcoholics, Mol Neurobiol, 2018. ,
, GHB receptor targets in the CNS: focus on high-affinity binding sites, vol.87, pp.220-228, 2014.
Comparing and combining gammahydroxybutyric acid (GHB) and naltrexone in maintaining abstinence form alcohol: an open randomized comparative study, Eur Neuropsychopharmacol, vol.17, pp.781-789, 2007. ,
Sodium oxybate to treat alcohol dependence: 20 years of clinical experience, Addict Biol, vol.18, pp.901-903, 2013. ,
Sodium oxybate in the prevention of alcohol relapses in alcohol dependent patients (GATE 2 study), Alcohol Alcohol, vol.48, pp.33-34, 2013. ,
Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial, CNS Drugs, vol.28, pp.743-752, 2014. ,
Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study, Drug Alcohol Depend, vol.70, pp.85-91, 2003. ,
Behavioral analyses of GHB: receptor mechanisms, Pharmacol Therap, vol.121, pp.100-114, 2009. ,
) ?Hydroxybutyric acid (GHB) is not an agonist of extrasynaptic GABAA receptors, PLoS One, vol.8, p.79062, 2013. ,
Alcohol-related harm to others in New Zealand: evidence of the burden and gaps in knowledge, N Z Med J, vol.125, pp.11-27, 2012. ,
Gamma-hydroxybutyric acid induced suppression and prevention of alcohol withdrawal syndrome and relief of craving in alcohol dependent patients, Alcologia, vol.7, pp.111-118, 1995. ,
, Guideline on the development of medicinal products for the treatment of alcohol dependence, European Medicines Agency, 2010.
Sex hormones in alcohol consumption: a systematic review of evidence, Addict Biol, 2017. ,
Gamma-hydroxybutyric acid for the treatment of alcohol withdrawal syndrome, The Lancet, vol.2, pp.787-789, 1989. ,
) ?Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study, Alcohol Clin Exp Res, vol.16, pp.673-676, 1992. ,
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence, Eur Neuropsychopharmacol, vol.23, pp.1432-1442, 2013. ,
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study, Alcohol Clin Exp Res, vol.35, issue.3, pp.523-531, 2011. ,
Baseline trajectories of heavy drinking and their effects on post-randomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment, Alcohol, vol.46, pp.121-131, 2012. ,
Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT, Alcohol Clin Exp Res, vol.38, pp.2647-2656, 2014. ,
Alcohol Clinical Trials Initiative (ACTIVE) Workgroup (2017) Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population, Lancet Psychiatry, vol.4, pp.469-476 ,
, Alcohol. Handb Exp Pharmacol, vol.170, pp.3393-3461, 2005.
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis, JAMA, vol.311, pp.1889-1900, 2014. ,
Total intravenous anaesthesia using propofol, gamma-hydroxybutyrate or midazolam in combination with sufentanil for patients undergoing coronary artery bypass surgery, Eur J Anaesthesiol, vol.14, pp.590-599, 1997. ,
Total intravenous anaesthesia with gamma-hydroxybutyrate (GHB) and sufentanil in patients undergoing coronary artery bypass graft surgery: a comparison in patients with unimpaired and impaired left ventricular function, Eur J Anaesthesiol, vol.15, pp.559-564, 1998. ,
The treatment gap in mental health care, Bull World Health Organ, vol.82, pp.858-866, 2004. ,
Measuring alcohol consumption in man-it is time for a change, Addiction, vol.101, pp.1215-1216, 2006. ,
The costeffectiveness and public health benefit of Nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model, BMJ Open, vol.4, pp.259-269, 2014. ,
Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses (Review), The Cochrane Collaboration, vol.2, pp.1-160, 2010. ,
Medications development to treat alcohol dependence: a vision for the next decade, Addict Biol, vol.17, pp.513-527, 2012. ,
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies, Alcohol Clin Exp Res, vol.37, pp.2128-2137, 2013. ,
Advances in Pharmacotherapy Development: Human Clinical Studies, Handb Exp Pharmacol, 2018. ,
The effects of ?hydroxybutyrate on sleep, Biol Psychiatry, vol.12, pp.273-288, 1977. ,
Treatment of narcolepsy with gammahydroxybutyrate. A review of clinical and sleep laboratory findings, Sleep, vol.9, pp.285-289, 1986. ,
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene, Biol Psychiatry, vol.73, pp.706-713, 2013. ,
PREDICT Study Team (2012) Results of a double-blind, placebocontrolled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study, Addict Biol, vol.18, pp.937-946 ,
Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy, Eur Neuropsychopharmacol, vol.26, pp.1941-1949, 2016. ,
Reduced drinking in alcohol dependence treatment, what is the evidence?, Eur Addict Res, vol.23, pp.219-230, 2017. ,
Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions, J Psychoactive Drugs, vol.38, pp.211-217, 2006. ,
, Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependenceAppendix 17d Pharmacological Interventions Forest Plots, NICE, vol.115, p.17, 2011.
Nalmefene reduces reward anticipation in alcohol dependence: an experimental functional magnetic resonance imaging study, Biol Psychiatry, vol.81, pp.941-948, 2017. ,
Van den Brink W (2018) Efficacy, tolerability and safety of low dose and high dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis, Eur Neurpsychopharamcol, vol.26, pp.1950-1959 ,
Alcohol dependence with a very high drinking risk level, a life threatening and seriously debilitating disease, Addict Biol, vol.23, pp.961-968, 2018. ,
Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union, Eur Neuropsychopharmacol, vol.23, pp.89-97, 2013. ,
Prevalence of and potential influencing factors for alcohol dependence in Europe, European Addiction Research, vol.21, pp.6-18, 2015. ,
Reduction of alcohol consumption and subsequent mortality in alcohol use disorders: systematic review and meta-analyses, J Clin Psychiatry, vol.74, pp.1181-1189, 2013. ,
Acamprosate for alcohol dependence, Cochrane Database Syst Rev, vol.9, p.4332, 2010. ,
Opioid antagonists for alcohol dependence, Cochrane Database Syst Rev, vol.12, p.1867, 2010. ,
Why we should consider sex (and study sex differences) in addiction research, Addict Biol, vol.21, pp.995-1006, 2016. ,
Russia-specific relative risks and their effects on the estimated alcohol-attributable burden of disease, BMC Public Health, vol.15, p.482, 2015. ,
Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention, Expert Opin Pharmacother, vol.15, pp.245-257, 2014. ,
Disulfiram efficacy in the treatment of alcohol dependence: a metaanalysis, PLoS One, vol.9, p.87366, 2014. ,
Alcoholism: a systems approach from molecular physiology to addictive behavior, Physiol Rev, vol.89, pp.649-705, 2009. ,
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption, Nat Med, vol.11, pp.35-42, 2005. ,
New pharmacological treatment strategies for relapse prevention, Curr Top Behav Neurosci, vol.13, pp.583-609, 2013. ,
Acamprosate produces its anti-relapse effects via calcium, Neuropsychopharmacology, vol.39, pp.783-791, 2014. ,
Treatment seeking for alcohol use disorders: treatment gap or adequate self-selection?, Eur Addict Res, vol.22, pp.277-285, 2016. ,
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study, Arch Gen Psychiatry, vol.67, pp.733-744, 2010. ,
Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels, Alcohol Clin Exp Res, vol.41, pp.179-186, 2017. ,
, WHO (2000) International guide for monitoring alcohol consumption and related harm, 2014.